| Date | Title | Description |
| 16.09.2024 | Life Sciences Virtual Investor Forum Agenda Announced for September 19th | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda f... |
| 24.07.2024 | BCLI Update - Progress Supports Our 10x Plus Value Range Potential | ACF Equity Research
FROM ACF EQUITY RESEARCH HEALTHCARE TEAM
LONDON, July 24, 2024 /PRNewswire/ --
NASDAQ: BCLI
READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE –... |
| 14.06.2024 | BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation | FROM ACF EQUITY RESEARCH HEALTHCARE TEAM
NASDAQ: BCLI
READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LO... |
| 18.10.2023 | Wegovy doesn’t work for everyone, and no one’s quite sure why | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a critical look at the mounting Ozempic panic, the case against a former me... |
| 27.01.2022 | BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit | NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief M... |
| 04.01.2022 | BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022 | NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Med... |
| 27.12.2021 | FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program | NEW YORK, Dec. 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for participants who... |
| 13.12.2021 | BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve | NEW YORK, Dec. 13, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data in Mu... |
| 07.12.2021 | BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing | NEW YORK and SOMERSET, N.J., Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, and Catalent (NYSE: CTLT), a global leader in enabling bio... |
| 02.12.2021 | BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND | NEW YORK, Dec. 2, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be presented at the 32nd ... |
| 29.11.2021 | BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium | NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of N... |
| 15.11.2021 | BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update | NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30, 2021, ... |
| 15.11.2021 | BRAINSTORM CELL THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | Company Overview
BrainStorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases includin... |
| 08.11.2021 | BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs | NEW YORK, Nov. 8, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future gro... |
| 08.11.2021 | BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs | NEW YORK, Nov. 8, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future gro... |
| 28.10.2021 | Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors | NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board... |
| 18.10.2021 | Brainstorm Cell Therapeutics : Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting | NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benef... |
| 14.10.2021 | Brainstorm Cell Therapeutics : Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosi... | NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOw... |
| 07.10.2021 | Brainstorm Cell Therapeutics : to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021 | NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correla... |
| 04.10.2021 | Brainstorm Cell Therapeutics : to Present at the 2021 Cell & Gene Meeting on the Mesa | NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head... |
| 01.10.2021 | BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS | NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Ef... |
| 05.08.2021 | BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update | NEW YORK, Aug. 5, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30, 2021 a... |
| 05.08.2021 | Brainstorm Cell Therapeutics : Announces Second Quarter 2021 Financial Results and Provides a Corporate Update | NEW YORK, Aug. 5, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended June 30, 2021 a... |
| 05.08.2021 | BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
USA - English USA - English | |
| 05.08.2021 | BRAINSTORM CELL THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | Company Overview
BrainStorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases includin... |
| 27.07.2021 | BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
USA - English USA - English | |
| 27.07.2021 | Brainstorm Cell Therapeutics : Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel | NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) appro... |
| 15.06.2021 | BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics : Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets | NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents ... |
| 15.06.2021 | Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets
USA - English USA - English | |
| 25.05.2021 | BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics : Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting | NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanis... |
| 25.05.2021 | BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
USA - English USA - English | |
| 26.04.2021 | BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics : Quarterly Report (SEC Filing - 10-Q) | Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended ... |
| 26.04.2021 | Brainstorm Cell Therapeutics : Quarterly Report (SEC Filing - 10-Q) | Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended ... |
| 26.04.2021 | BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
USA - English USA - English | |
| 26.04.2021 | BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | Company Overview
BrainStorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases includin... |
| 26.04.2021 | BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics : Announces First Quarter 2021 Financial Results and Provides a Corporate Update | NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 202... |
| 26.04.2021 | BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update | NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 202... |
| 19.04.2021 | BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update | NEW YORK, April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shar... |
| 24.03.2021 | BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
USA - English
USA - English | |
| 22.02.2021 | BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program
USA - English
USA - English | |
| 22.02.2021 | Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway | When BrainStorm Cell Therapeutics broke out the abysmal numbers in its Phase III trial, the biotech insisted that the FDA was eager to review the data — given the signal they had identified in a subgroup of amyotrophic lat... |
| 09.02.2021 | BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan
USA - English
USA - English | |
| 04.02.2021 | BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update
USA - English
USA - English | |
| 20.01.2021 | BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
USA - English
USA - English | |
| 18.12.2020 | BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
USA - English
USA - English | |
| 14.12.2020 | BrainStorm Announces NurOwn® Expanded Access Program
USA - English
USA - English | |
| 23.11.2020 | BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
USA - English
USA - English | |
| 17.11.2020 | BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
USA - English
USA - English | |
| 26.10.2020 | Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility
USA - English
USA - English | |
| 19.10.2020 | BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference
USA - English
USA - English | |
| 15.10.2020 | BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update
USA - English
USA - English | |
| 30.09.2020 | BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting
USA - English
USA - English | |
| 29.09.2020 | BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing
USA - English
USA - English | |
| 16.09.2020 | Brainstorm Announces Grant of a New Japanese Patent for NurOwn®
USA - English
USA - English | |
| 25.08.2020 | BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)
USA - English
USA - English | |
| 19.08.2020 | BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease
USA - English
USA - English | |
| 07.09.2018 | Ovid exec Yaron Werber crosses back to Cowen; Saqib Islam promoted to SpringWorks' first CEO slot | Yaron Werber
→ While a number of analysts have been seen migrating to the front lines of biotech, Yaron Werber is moving in the opposite direction. After rotating through a couple of roles at rare disease biotech Ovid Ther... |
| 04.09.2018 | Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark | → BrainStorm Cell Therapeutics $BCLI has appointed Novartis vet Arturo Araya as chief commercial officer. Araya had been global head of commercial of Novartis’ Cell and Gene Therapies Unit and has been on the board at Br... |
| 18.07.2016 | Brainstorm’s rally fizzles after investors turn sour on questionable ALS data | Brainstorm Cell Therapeutics worked hard Monday morning to make the case that a small Phase II study of its lead stem cell therapy for amyotrophic lateral sclerosis (ALS) provided plenty of reasons for optimism about Pha... |
